Teladoc Health, Inc. (NYSE:TDOC) Receives $9.60 Average Price Target from Brokerages

Teladoc Health, Inc. (NYSE:TDOC) has received a consensus rating of “Hold” from the eighteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.60.

TDOC has been the subject of a number of analyst reports. BMO Capital Markets began coverage on shares of Teladoc Health in a research note on Thursday, November 13th. They set a “market perform” rating and a $8.00 target price for the company. Evercore ISI dropped their price target on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research note on Thursday, October 30th. Citigroup raised their price objective on shares of Teladoc Health from $9.50 to $10.50 and gave the stock a “neutral” rating in a report on Tuesday, October 21st. Barclays started coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Finally, Zacks Research cut Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $7.23 on Thursday. The firm has a 50 day moving average of $7.72 and a two-hundred day moving average of $7.80. The stock has a market capitalization of $1.28 billion, a PE ratio of -5.64 and a beta of 2.04. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. Teladoc Health has a 52 week low of $6.35 and a 52 week high of $15.21.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The business had revenue of $626.44 million for the quarter, compared to analysts’ expectations of $625.66 million. During the same period last year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. On average, research analysts predict that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carlos Nueno sold 3,897 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the transaction, the insider directly owned 27,175 shares in the company, valued at approximately $203,540.75. The trade was a 12.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,288 shares of company stock worth $251,684 over the last three months. 0.58% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Nuveen LLC purchased a new position in shares of Teladoc Health during the 1st quarter worth $11,789,000. Dimensional Fund Advisors LP grew its position in shares of Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares during the period. Vanguard Group Inc. lifted its position in Teladoc Health by 7.0% during the first quarter. Vanguard Group Inc. now owns 19,752,338 shares of the health services provider’s stock worth $157,229,000 after buying an additional 1,289,183 shares during the period. Allianz Asset Management GmbH boosted its stake in Teladoc Health by 189.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in Teladoc Health in the 2nd quarter valued at about $8,729,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.